Y mAbs Therapeutics Company Overview
About Y mAbs Therapeutics
Y-mAbs Therapeutics (NASDAQ:YMAB) is a biopharmaceutical company focused on the development and commercialization of novel antibody-based therapies for the treatment of cancer and rare diseases. Their operations span from early-stage research to the commercialization of their products, aiming to improve patient outcomes with cutting-edge treatments. Y mAbs Therapeutics is dedicated to advancing a diverse pipeline of therapeutic candidates, including projects targeting pediatric cancers and other life-threatening conditions. Their objective is to translate groundbreaking scientific research into transformative therapies for patients who currently have limited treatment options, emphasizing a commitment to innovation and patient care in the medical field.
Snapshot
Operations
Products and/or services of Y mAbs Therapeutics
- DANYELZA, an FDA-approved treatment for pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor.
- Omburtamab, an investigational radioimmunotherapy under development for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma and other potential indications.
- GD2-GD3 Vaccine, an investigational cancer vaccine aimed at stimulating the immune system to attack neuroblastoma cells, currently in early clinical development.
- naxitamab, an investigational GD2-directed antibody being evaluated for various types of cancers, including osteosarcoma and other solid tumors, in combination with other therapies.
- SADA technology, a proprietary drug development platform designed to create next-generation antibody-drug conjugates and radioimmunotherapies with potential applications across multiple cancer types.
- GD2-BiTE, an investigational bispecific T-cell engager targeting GD2-positive cancers, leveraging the immune system to destroy cancer cells, currently in pre-clinical development.
Y mAbs Therapeutics executive team
- Mr. Michael RossiCEO, President & Director
- Mr. Thomas GadFounder, Chief Business Officer & Vice Chairman
- Mr. Peter P. Pfreundschuh CPAExecutive VP, CFO & Treasurer
- Mr. Joris Wiel Jan WilmsSenior VP & COO
- Dr. Torben Lund-Hansen M.Sc., Ph.D.Senior VP & CTO
- Ms. Courtney DuganVP & Head of Investor Relations
- Mr. John W. LaRocca Esq.Senior VP, General Counsel, Secretary & Chief Legal Officer
- Dr. Norman D. LaFrance FACNP, FACP, M.D.Chief Development Officer & Chief Medical Officer
- Mr. Doug GentilcoreSenior VP & Head of DANYELZA Business Unit
- Ms. Natalie TuckerSenior VP & Radiopharmaceutical Business Unit Head